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Abstract
Stem cell pluripotency and differentiation are global 
processes regulated by several pathways that have 
been studied intensively over recent years. Nitric 
oxide (NO) is an important molecule that affects gene 
expression at the level of transcription and translation 
and regulates cell survival and proliferation in diverse 
cell types. In embryonic stem cells NO has a dual role, 
controlling differentiation and survival, but the molecular 
mechanisms by which it modulates these functions are 
not completely defined. NO is a physiological regulator 
of cell respiration through the inhibition of cytochrome 
c oxidase. Many researchers have been examining 
the role that NO plays in other aspects of metabolism 
such as the cellular bioenergetics state, the hypoxia 
response and the relationship of these areas to stem 
cell stemness.
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Core tip: Increasing research interest has focused on the 
role of nitric oxide (NO) in regulating many physiological 
functions such as metabolism, the hypoxia response, 
pluripotency, and stem cell differentiation. NO has been 
proven to act as a powerful agent for promoting the 
maintenance of cell pluripotency and survival, thus 
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explaining how it can act as an alternative factor for the 
maintenance of certain cultured cell lines.
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INTRODUCTION
Nitric oxide (NO) is a short-lived free radical synthesised 
via the L-arginine to L-citrulline pathway, which is 
mediated by nitric oxide synthase, NOS1 (neuronal 
NOS), NOS2 (inducible NOS), and NOS3 (endothelial 
NOS)[1], in most animal cells[2]. NO reacts with molecules 
such as oxygen, superoxide or metals, nucleic acids, 
and proteins. NO is quickly oxidised into nitrate and 
nitrite, which are now considered as non-inert products 
because they are a source of NO through their reduction 
by reductase enzymes when the endogenous L-arginine/
NOS pathway is dysfunctional[3]. In addition to serving 
as a germicide in the immune system as part of the 
inflammatory response and as a neurotransmitter 
in the central nervous system, NO acts as a second 
messenger and has multiple biological effects implicated 
in a variety of physiological functions in mammals, such 
as the regulation of blood pressure via smooth muscle 
relaxation and inhibition of platelet aggregation[4-7]. 
Moreover, it has been shown that it affects gene 
expression at the level of transcription and translation 
and regulates cell survival and proliferation in diverse 
cell types[8,9]. Furthermore, NO plays a role in growth, 
survival, proliferation, differentiation, as well as in the 
pathology of illnesses such as cancer, diabetes, and 
neurodegenerative diseases[10,11]. In addition, it has 
been reported that NO is involved in the control of heart 
functions and cardiac development[12,13]. 
The presence and concentration of other free radicals 
are critical factors that influence the effects of NO on 
cellular processes. For example, it has been described 
that low concentrations of NO inhibit cytochrome c oxidase 
(CcO), which catalyses the final step of the mitochondrial 
transport chain, competing with O2 in a reversible 
manner[14,15]. Nevertheless, high levels of NO may cause 
nitrosylation of protein thiols and perhaps the removal 
of iron from iron-sulphur centres[16,17]. CcO, as catalyst 
of the central step of oxidative phosphorylation and 
adenosinetriphosphate (ATP) generation, regulates cellular 
oxygen consumption. The physiological concentration 
of NO modulates CcO activity, depending on the 
concentration of intracellular oxygen and the redox state 
of CcO. This interaction between CcO and NO allows the 
detection of changes in oxygen concentration and the 
initiation of adaptive responses. This indicates that NO 
might be a physiological regulator of cellular respiration 
and metabolism. Furthermore, NO has been described 
to have an important role in regulating the hypoxia 
response[15,18,19]. 
On the other hand, it has been reported that low 
concentrations of NO have a direct effect on processes 
such as cell proliferation and survival[8]. In RINm5F 
cells homeostatic concentrations of NO (1-10 μmol/L) 
can initiate signalling pathways implicated in survival 
actions[20]. Moreover, higher NO concentrations, induced 
by the inflammatory response, can cause oxidative and 
nitrosative stress, and apoptosis. These actions are partly 
responsible for cell death in chronic and degenerative 
diseases. Pharmacological treatment with high NO 
concentrations promote embryonic stem cell (ESC) 
differentiation[9,21-23]. However, the functional significance 
of high NO concentrations on differentiation in vivo has 
not yet been demonstrated.
It has been clearly shown that NO has an important 
role as regulator of many physiological functions, and 
has thus become a target of interest in the fields of 
metabolism, the hypoxia response, pluripotency, and 
stem cell differentiation. This review aims to describe 
the progress on understanding the role of NO in these 
interrelated biological processes.
MECHANISM OF NO ACTION IN STEM 
CELL BIOLOGY 
The downstream effects of NO can be mediated in 
cyclic guanosine monophosphate (cGMP) dependent 
or independent ways[24-26]. When acting independently 
of cGMP, it has been shown that NO interacts with 
metal complexes, oxygen (O2), super-oxide anion 
(O2•-) and CcO[15]. These interactions have different 
effects depending on the amount of NO present. Protein 
nitrosylation and nitration can occur when NO interacts 
with oxygen species, which happens more frequently 
at high levels of NO[27]. On the other hand, cGMP-
dependent effects are mediated by the NO receptor, 
soluble guanylylcyclase (sGC). sGC is a heterodimeric 
hemoprotein composed of alpha (sGCa) and beta (sGCβ) 
subunits[28]. NO activates sGC by interacting with its 
hemo group and catalysing the conversion of GTP into 
cGMP. cGMP controls a variety of physiological effects in 
several tissues by interacting with downstream effectors 
such as a family of cGMP-dependent protein kinases 
(PKG), cGMP-dependent phosphodiesterases, and 
cyclic nucleotide gated channels[24]. In addition, triple 
NOS knockout mice, where NO production is abolished, 
have been shown to have a reduced survival rate and 
lower numbers of offspring[29]. Thus, it was proposed 
that NO/cGMP signalling plays a significant role in 
embryonic development and cell differentiation. This 
hypothesis has gained additional support from studies 
that show differential expression and function of various 
NO signalling components in ESCs and differentiated 
cells[25,26,30]. Although it remains unclear whether the 
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action of NO on stem cell biology is mediated via the 
cGMP pathway, it has been shown that the effects of NO 
on bone marrow stem cell potency and differentiation 
are independent of the sGC-cGMP pathway[31,32]. Recent 
studies have also shown that NO can regulate protein 
function via the nitrosylation of sGC cysteine residues[33]. 
Indeed, NO has been reported to modulate transcription 
factor function via Cys-nitrosylation[34]. It was concluded 
that the effects of NO on stem cell pluripotency and 
differentiation are independent of the sGC-cGMP 
pathway[5]. The mechanisms by which NO modulates 
the differentiation of ESCs remain unclear. Intriguingly, 
NO appears to act independently of the LIF/Stat3 
pathway, as NO does not induce Stat3 phosphorylation in 
ESCs[8]. Moreover, the expression of Nanog is LIF/Stat3 
independent, and Nanog over-expression in the absence 
of LIF is able to maintain ESC pluripotency[35].
NO REGULATES STEM CELL 
PLURIPOTENCY AND DIFFERENTIACION
The study of stem cells has gained considerable 
interest in recent years because they potentially offer 
an unlimited source of cells for therapeutic purposes. 
Many research groups have participated in efforts 
to expand and characterise populations of ESCs and 
induced-pluripotent stem cells (iPSCs), and to identify 
ways of directing their differentiation towards particular 
tissue types. In this context, the identification of 
small molecules that act on specific cell signalling 
pathways involved in embryonic development might 
be instrumental in the design of protocols that can 
efficiently control cell “stemness” and stem cell 
differentiation.
NO is, potentially, one such small molecule, with 
evidence supporting a dual role for it in the control 
of ESC differentiation and tissue morphogenesis. 
It is important to note that the effects of NO on 
differentiation and the maintenance of pluripotency 
are dose dependent. Moreover, while it is generally 
considered to be an inducer of apoptosis[36,37], it has 
also been shown to protect certain cell types from 
programmed cell death[38].
NO has been demonstrated to have the potential to 
influence the proliferation and differentiation cascades 
of certain cell types but its effect varies widely from cell 
to cell. For example, the proliferation and differentiation 
of human skin cells is modulated by NO[39], a finding 
that helps explain the pathophysiology of human skin 
diseases. NO causes growth inhibition of immortalised 
human oral keratinocytes and primary oral cancer cells 
(HN4) mainly via apoptotic cell death induced indirectly 
by stimulating the differentiation of both immortalised 
and malignant oral keratinocytes[2]. This suggests that 
the generation of NO in human skin diseases is not 
directly associated with local cell destruction, in contrast 
to observations in several other human diseases[39]. 
Our group has reported that the exposure of ESCs to 
low concentrations of the NO donor, diethylenetriamine 
NO adduct (DETA-NO), prevents the loss of expression 
of self-renewal genes and blocks mouse and human 
ESC differentiation. Similarly, constitutive NOS3 over-
expression in cells grown under LIF withdrawal conditions 
maintained the expression of pluripotency markers[8]. 
On the other hand, exposure to high concentrations of 
DETA-NO promotes the differentiation of mouse ESCs 
(mESCs) by down-regulating Nanog and Oct4, the two 
master genes that control the pluripotent state[9]. 
Low concentrations of NO modulate pluripotency gene 
expression
It has been shown that low amounts of DETA-NO (2-20 
μmol/L) delay the differentiation of human embryonic 
stem cells (hESCs), since the addition of NO induces 
an increase in the expression of Nanog, Oct4 and Sox2 
to levels even higher than when cells are cultured with 
basic fibroblast growth factor (bFGF). Moreover, the 
cell surface antigen SSEA-4, which disappears following 
five passages under bFGF withdrawal, is retained 
when the growth medium is supplemented with NO. 
In addition, NO represses some differentiation markers 
(Brachyury, Gata4, Gata6, Fgf5 and Fgf8), which are 
present in the absence of bFGF. Similar observations 
were also seen in mESCs grown in the absence of 
LIF and supplemented with NO, which also induced 
Oct4 and Nanog protein expression, together with a 
decrease in the expression of the aforementioned early 
differentiation genes (Figure 1). Constitutive over-
expression of NOS3 in cells cultured in the absence of 
LIF protected them from apoptosis and promoting 
cell survival[8]. 
NO has also been shown to play an important role 
in other cell types, such as multipotent resident cardiac 
stem cells and adult bone marrow cells (BMCs)[40,41]. 
NOS3-generated NO plays an important role in car-
diomyocyte proliferation and maturation during early 
neonatal heart development[42]. Furthermore, a recent 
study using a porcine model has shown that activation 
of the NO pathway directs BMCs toward a preferential 
cardiomyogenic phenotype and also stimulates cell 
proliferation[43].
Genomic studies carried out by our group indicate 
that low concentrations of NO in mESCs regulate 
apoptosis, survival and the hypoxia response, areas 
that will be looked at more closely in the remainder of 
this review. 
Regulation of differentiation by high concentrations of 
NO
NO plays an important role in development: It 
has been reported that NO may act as an essential 
negative regulator of cell proliferation during tissue 
differentiation and organ development in Xenopus and 
Drosophila. In addition, NO production is crucial for 
the establishment of ordered neuronal connections in 
the fly’s visual system, indicating that NO affects the 
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Sox 17 (Figure 1)[9].
The use of NO in differentiation protocols for the 
generation of different germinal lines: The first 
report of an efficient differentiation protocol using mESCs 
treated with NO was published by Kanno et al[45] in 2004. 
They demonstrated that NO promoted differentiation in 
part through its effects on cell survival, leading to the 
differentiation of mESCs into CMs[45]. Other groups have 
identified the role of cGMP signalling components and 
NO in cardiac development, as well as molecules that 
may regulate early cardiomyogenesis in ESCs via NO-
dependent pathways, such as polyphenol curcumin and 
ascorbic acid[25,46-48]. In addition, it has been shown that 
other signalling pathways besides NO are involved in 
oxytocin-stimulated cardiomyogenesis[49].
It has been reported that NO is involved in vascular 
tissue differentiation. Because of the pivotal role played by 
NO in the biology of endothelial cells (ECs)[50] and its role 
in angiogenesis[51], it was hypothesised that it may also 
play a role in endothelial development. This was tested 
by studying the effect of differential expression of NO 
signalling components, or conversely of NOS inhibition, 
on endothelial differentiation. These studies indicate that 
NO is important for later endothelial development and 
function, although other signalling pathways appear to 
play a greater role in early development[52]. Although 
differentiation protocols for generating ECs from ESCs 
do not include NO-like active small molecules, the 
expression of endothelial NO synthase in these cell types 
is considered to be a characteristic of mature ECs[53,54]. 
Moreover, it has been demonstrated that NO/cGMP 
signalling molecules regulate neural lineage commitment 
and govern neural precursor differentiation, suggesting 
that NO/cGMP signalling contributes to the development 
of neural precursors and enhances the differentiation of 
precursors toward functional neurons[55,56]. Furthermore, 
it was reported that NO exposure to NPCs leads to a 
decrease in neuronal differentiation paralleled by an 
increase in astroglial differentiation. Neuron restrictive 
silencing factor1/repressor element-1 silencing transcription 
factor has been shown to play an essential role in the 
regulation of neurogenesis and is required for NO-
mediated neural to glial fate induction[57].
It has been reported that NO modulates the growth 
and differentiation of human erythroid and myeloid 
cells from CD34+ BMCs in vivo[58], promotes bone and 
chondrocyte terminal differentiation[59], stimulates 
pre-adipocyte differentiation in rat[60] and mediates 
osteoblastic differentiation[61]. 
Bone marrow multipotent adult progenitor cells (MAPCs) 
can be purified and cultured from humans, rats and 
mice. MAPCs express Oct4 and are able to differentiate 
into multiple cell lineages including endothelial cells and 
neurons[62,63]. Importantly, NO appears to play a key role 
in both the maintenance of MAPC multipotency as well 
as in promoting their endothelial differentiation. In fact, 
it has been shown that NO inhibits the proliferation of 
MAPCs when treated with high concentrations of different 
acquisition of differentiated neural tissue[7]. Moreover, 
blocking NO production in neural precursor cells (NPCs) 
isolated from the ventricular zone of postnatal mice, 
resulted in increased proliferation[44]. In ESCs, it has 
been demonstrated that NO generation is required for 
cardiomyogenesis, since NOS inhibitors prevent the 
maturation of terminally-differentiated cardiomyocytes 
(CMs). Moreover, it has been shown that the differentiation 
of mESCs toward a cardiac phenotype is arrested by 
NO synthase inhibitors, which can in turn be readily 
rescued by NO donors[13]. NOS2 and NOS3 isoforms 
are prominently expressed during the early stages 
of cardiomyogenesis until NOS expression starts 
to decline around E14.5[13]. In the same context, 
undifferentiated ESCs are known to express high 
levels of NOS3. During differentiation, NOS3 levels 
decrease, whereas NOS2, NOS1, sGCa1, sGCβ1, and 
PKG levels significantly increase, suggesting that NO 
could be involved in the early differentiation events or 
physiological processes of ES cells or ES derived-cell 
lineages[25].
On the other hand, high DETA-NO concentrations 
(0.25-1.0 mmol/L) promote mESC differentiation 
by down-regulating Nanog and Oct4 expression. The 
repression of Nanog by NO is dependent on p53 
activation associated with covalent modifications, such 
as Ser315 phosphorylation and Lys379 acetylation. In 
addition, exposure to high DETA-NO concentrations 
(0.5 mmol/L) increases the expression of definitive 
endoderm markers, such as FoxA2, Gata4, Hfn1-β and 
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Figure 1  The dual roles of nitric oxide in stem cell pluripotency and 
apoptosis. Low amounts of nitric oxide (NO) induce the expression of Nanog, 
Oct4 and Sox2. This confers protection from apoptosis by down-regulating pro-
apoptotic genes including Casp7, Casp9, as well as up-regulating the anti-
apoptotic genes Bcl-2 and Birc6. High NO concentrations promote apoptosis 
markers, such as Poly (ADP-ribose) polymerase degradation, cleaved caspase-3, 
and increased p53 protein levels. Cells expressing Hsp70, a cyto-protective 
gene, are resistant to oxidative stress and enter into a differentiation program. 
Differentiation events are initiated by the down-regulation of Nanog and Oct4 and 
the expression of definitive endoderm markers, such as Pdx1 and Gata4.
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NO donors. In addition, NO promotes the endothelial 
differentiation of MAPCs through a cGMP-independent-
mechanism[5]. 
A protocol for inducing the differentiation of ESCs 
into definitive endoderm has been developed in our 
laboratory. Exposure of mESC to 0.5 mmol/L DETA-NO 
induces early differentiation events with the acquisition 
of an epithelial morphology and expression of definitive 
endoderm markers, such as FoxA2, Gata4, Hfn1-β and 
Sox 17. This phenotype was increased when cells were 
also treated with valproic acid for 10 d[9]. 
CONTROL OF APOPTOSIS AND 
SURVIVAL BY NO
Many reports have indicated that NO down-regulates 
pro-apoptotic response in mESCs and up-regulates anti-
apoptotic responses by regulating Bcl2 family proteins[64]. 
mESCs over-expressing Bcl2 are characterised by long-
term maintenance of an undifferentiated state and 
pluripotency. In addition, these cells maintain their 
potential to differentiate into mature cell types[65]. This 
role of NO depends on its local concentration. At low 
non-toxic levels, NO induces resistance to tumour 
necrosis factor-a (TNFa)-induced hepatotoxicity[66], 
inhibits Fas-induced apoptosis in B lymphocytes[67], and 
modulates CD95-induced apoptosis in T-lymphocytes[68]. 
Moreover, in carcinogenesis, low NO levels can promote 
the development and growth of tumour cells, while 
high levels may be toxic to them[2]. It has been proved 
that low concentrations of NO donors can protect 
murine bone marrow stromal cells against spontaneous 
apoptosis[32].
We have reported that NO generation by NOS3 
overexpression and low levels of DETA-NO contribute 
to the survival of pancreatic beta cells through the 
activation of IGF-1 and insulin-induced survival 
pathways[23]. Our group has also reported that low level 
exposure (2-20 μmol/L) to DETA-NO protects ESCs from 
apoptosis. These NO actions involve: (1) decreased 
caspase-3 activity, combined with the degradation 
of Poly (ADP-ribose) polymerase; (2) decreased 
expression of pro-apoptotic genes, such as Casp7, 
Casp9, Bax and Bak1; and (3) increased expression of 
the anti-apoptotic genes, Bcl-2 and Birc6 (Figure 1). 
Similarly, constitutive NOS3 over-expression in cells 
deprived of LIF protects them against apoptosis[8].
On the other hand, several studies show that NO 
induces apoptosis in different cell types, including 
pancreatic beta cells[69,70], thymocytes[71], hepatocytes[72], 
among others[73,74]. It has been reported in ESCs that 
the nitrosative stress induced by exposure to high 
levels of DETA-NO, induces apoptotic events in part of 
the ESC population. Other parts of the ESC population 
are resistant to nitrosative stress and express the 
cytoprotective genes, heme-oxigenase-1 and Hsp70. 
Moreover, the resistant cells enter into a differentiation 
program (Figure 1)[9].
NITRIC OXIDE, HYPOXIA AND STEM 
CELL METABOLISM
As we have seen in the previous sections, there is very 
clear evidence indicating that NO can regulate cell 
pluripotency and differentiation, but, as mentioned at 
the beginning of this review, the molecular mechanisms 
behind these functions are still unclear[8]. The metabolic 
profile of pluripotent stem cells (PSCs) undergoes 
substantial changes during differentiation. Indeed, there 
is a shift from glycolytic to oxidative metabolism[75]. 
On the other hand, cellular response to hypoxia is also 
involved in the control of pluripotency. Hypoxia affects 
many physiological processes during the early stages 
of mammalian ontogeny, as it is a key feature of this 
stem cell niche. Moreover, it has been reported that 
low oxygen tension and low NO concentrations prevent 
the differentiation of hESC colonies and are required to 
maintain the majority of cells within a colony in a fully 
pluripotent state[8,76]. Therefore, in this review we will 
address the relationship between NO and the regulation 
of cellular respiration, as well as how they combine to 
effect cellular responses to hypoxia, energy metabolism 
and pluripotency.
PSC metabolism
PSCs have a short G1 cell cycle phase, which acts to 
limit the growth and differentiation potential of PSCs[77]. 
To facilitate rapid cell duplication, PSCs must balance 
energetic and biosynthetic demands, which is similar 
to what happens in cancer cells. Several studies have 
shown that mESCs, hESCs and iPSCs have an elevated 
dependence on glycolysis under aerobic conditions 
compared to differentiated cell types[78-81]. In cancer cells 
and human PSCs, a high glycolytic flux provides sufficient 
ATP and anabolic precursors for rapid proliferation, with 
the pentose-phosphate pathway generating ribose-5-
phosphate for nucleotides and NADPH-reducing power 
for nucleotide and lipid biosynthesis[82,83]. Thus, aerobic 
glycolysis is a common feature of PSC and cancer cell 
metabolism in culture[84,85].
During PSC differentiation, energy production is 
mainly obtained from oxidative phosphorylation. Studies 
on mitochondrial morphology and mitochondrial DNA 
have shown that ESCs contain fewer mitochondria, in 
a less mature state than in differentiated cells[83]. The 
maximum human PSC respiration capacity is limited and 
it has been suggested that low expression of electron 
transport chain complex Ⅳ cytochrome c oxidase 
subunits, which donate electrons to oxygen, may be the 
cause of this decreased level of respiratory activity[86].
Efforts are being made to understand the molecular 
mechanisms that regulate energy metabolism in PSCs 
and the changes that occur during differentiation or 
reprogramming events. Glycolysis-regulating enzymes, 
including hexokinase and lactate dehydrogenase, are 
highly expressed in PSCs and maybe controlled by the 
mammalian target of rapamycin and phosphoinositide 
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3-kinase (PI3K) signalling pathways, which regulate 
glycolytic genes in other cell contexts. Glycolytic and 
Mitochondrial Oxidative Phosphorylation (OXPHOS) 
pathway gene expression and DNA methylation patterns 
also change during pluripotency reprogramming[80]. 
A number of possible mechanisms for the low levels of 
respiration and ATP production in PSCs have been reported, 
including limited pyruvate access to mitochondria due to 
an inactive pyruvate dehydrogenase (PDH) complex and 
the expression of uncoupling protein 2 (UCP2)[78,81]. The 
same mechanisms have also been found in cancer cells. 
The PDH-mediated conversion of pyruvate to acetyl-
CoA and its entry into mitochondria is blocked in hypoxic 
cancer cells by hypoxia inducible factor-1a (HIF1a), 
which induces pyruvate dehydrogenase kinase 1 (PDK1) 
expression and inactivates PDH phosphorylation[87]. Also, 
several types of cancer overexpress UCP2[87]. In addition 
to these examples, other mechanisms have also been 
proposed for the hypoxia response of PSCs but all with 
the same end result, i.e., reduced energy production by 
OXPHOS and increased flux through the PSC glycolytic 
pathway.
HIF regulates pluripotency
PSCs have distinct metabolic requirements and cell 
reprogramming requires a shift from oxidative to 
glycolytic metabolism[78-81]. However, it is still unknown 
how stem cells activate mitochondrial oxidative pho-
sphorylation pathways during differentiation.
Human iPSCs are usually reprogrammed from 
somatic cells and are metabolically similar to hESCs[78,80]. 
Therefore, a metabolic switch from an oxidative to a 
highly glycolytic state ought to take place during iPSC 
formation. The dependency of stem cells on glycolysis 
to produce ATP could be an adaptation to low oxygen 
tensions in vivo, given that hypoxia appears to be a 
key feature of “stemness”[88,89]. Supporting this idea, 
low oxygen levels have been shown to be beneficial for 
hESCs, adult stem cells[76,90-92] and cancer cells[93,94].
HIF-1a and HIF-2a have essential roles during 
development. Increasing evidence suggests that 
HIFs can activate factors involved in pluripotency and 
regulate stem-cell properties in both cancerous and 
normal cells. For example, it has been suggested 
that HIF-2a activates one of the core pluripotency 
master genes such as Oct4[76,93-98]. This and other 
evidence indicate that HIF is a regulator of stem cell 
properties[88,99-102]. Because of this, there is now a 
high degree of interest in understanding the hypoxia 
mechanism involved in cell reprogramming and the 
maintenance of pluripotent states. 
NO regulates mitochondrial respiration and modulates 
metabolic changes
It has been reported that NO interacts with oxygen 
bound to CcO, the last enzyme of the electron transport 
chain[15]. CcO is located on the inner mitochondrial 
membrane and contains two heme and two copper 
centres. The cytochrome’s heme iron and copper 
molecules (in their reduced form) constitute the binding 
site for oxygen as it catalyses the reduction of oxygen 
to water. This process is related to the transport of 
protons into the mitochondrial inter-membrane space. 
In this last step, water is generated from oxygen and 
protons to drive the ATPase[103]. During normoxia the 
enzyme is predominantly in an oxidised state, while 
during hypoxia the reduced state predominates. 
CcO has a greater affinity for NO than for oxygen, 
suggesting that this interaction may be significant under 
certain physiological conditions. If true, it would make 
NO a physiological regulator that acts directly on the 
mitochondrial respiratory chain[14,15,104]. This reaction 
and its biological consequences are dependent on the 
redox state and turnover of CcO, the in situ oxygen 
concentration and the activity of NO synthase[105].
At high oxygen and NO concentrations, CcO is in its 
oxidised state and NO is metabolised into nitrite and 
nitrate; whereas at lower oxygen concentrations, CcO 
is mainly reduced and NO is not metabolised. Thus, 
under lower oxygen concentrations, NO accumulates 
in the intracellular microenvironment, with important 
implications for the balance between glycolysis and 
OXPHOS. Interaction between NO and CcO changes the 
availability of intracellular oxygen and the generation of 
reactive oxygen species (ROS). This results in changes 
to cell signalling pathways, especially oxygen-sensitive 
ones, which determine the nature of cellular hypoxia 
responses[106]. 
At low oxygen concentrations mitochondrial ATP 
generation decreases due to reduced respiratory activity. 
This results in increased levels of its precursor, AMP, 
and activation of AMP-activated kinase (AMPK), which 
is a critical regulator of cellular energy homeostasis 
and crucial for adapting to low oxygen (hypoxic) 
conditions[107]. The activation of AMPK promotes catabolic 
pathways, including glucose transport, gluconeogenesis, 
respiration, and the use of oxygen-independent energy 
sources. Moreover, it acts to down-regulate anabolic 
pathways. 
NO inhibits mitochondrial respiration and increases 
glycolysis, thus maintaining normal cellular ATP levels 
(Figure 2). It has been reported that astrocyte energy 
production is maintained following NO-mediated inhibition 
of CcO by up-regulating glycolysis[19]. After the NO-
induced inhibition of respiration, there is a cGMP-
independent increase in the activity of 6-phosphofructo-
1-kinase, a master regulator of glycolysis[108], and 
an increase in the concentration of its most powerful 
positive allosteric activator[109], fructose-2,6-bisphosphate 
(F2,6P2). Also, it has been shown that NO-induced 
glycolysis activation is dependent on the phosphorylation 
of AMPK resulting in increased 6-phosphofructo-2-
kinase activity and protection against apoptosis[19]. On 
the other hand, it has also been described that NO 
regulates HIF-1a[18]. This activity of NO is an important 
additional mechanism by which NO might modulate cellular 
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responses to hypoxia in mammalian cells (Figure 2).
NO and the hypoxia response
Most cells respond to exposure to low oxygen concentrations 
through the activation of hypoxia-responsive genes such 
as erythropoietin, NOS2 and glycolytic enzymes. This 
adaptive response to hypoxia is mediated by HIF-1a, 
which regulates the expression of a large number of 
genes that control cellular responses to reduced oxygen 
availability[110].
HIF is composed of two subunits, the constitutively-
expressed beta-subunit (HIF-1β), and the alpha 
subunit (HIF-1a), whose expression is highly sensitive 
to oxygen concentration and accumulates rapidly under 
hypoxic conditions[111,112]. HIF-1a protein degradation 
is tightly regulated by oxygen levels through two 
mechanisms, both involving HIF-1a hydroxylation. The 
first consists of the prolyl hydroxylation of two HIF-1a 
proline residues, targeting the protein for E3-ubiquitin-
ligase mediated ubiquitination. This complex contains 
the von-hippel-lindau tumour suppressor protein (VHL), 
which binds to hydroxylated HIF-1a. The second 
mechanism is mediated by asparagine hydroxylation 
of HIF-1a residues located in aprotein domain that 
is involved in interaction with the p-300 transcription 
activator. The result of this hydroxylation is the 
inhibition of target genes. Under hypoxic conditions, 
the hydroxylation of HIF-1a does not occur. This allows 
HIF-1a to dimerise with HIF-1β and translocate to 
the nucleus. Once in the nucleus, the dimer recruits 
the p300 and CBP co-activators, which induces the 
expression of its transcriptional targets, via binding to 
hypoxia-responsive elements (HERs), located in the 
promoter region of target genes[113,114].
Mitochondria play an important role in sensing cellular 
oxygen concentrations. Studies using pharmacological 
inhibitors have shown that the hypoxic regulation of 
HIF-1a is dependent on mitochondrial function through 
inhibition of the respiratory chain[115,116]. As NO inhibits 
CcO, it is possible that NO modulates the hypoxia 
response through HIF-1a.
NO regulates the accumulation of HIF-1a
Numerous studies have shown that NO affects HIF-1a 
accumulation. However, there is some controversy as to 
whether it promotes HIF-1a stabilisation[117-119] or HIF-
1a destabilisation[120-122]. Moncada et al[6] demonstrated 
that NO-induced HIF-1a regulation occurs via both 
mitochondria-dependent and -independent pathways 
(Figure 2). This work was performed using the HEK-293 
cell culture model where NO was generated inside cells in 
a finely controlled manner using a tetracycline-regulated 
inducible NOS2 expression system. They demonstrated 
that NO concentrations of 400 nmol/L prevented the 
accumulation of HIF-1a under hypoxic conditions, in 
a mitochondria-dependent manner. This study, also 
showed that intracellular high NO levels (> 1 µmol/L) 
always resulted in HIF-1a stabilization, under both 
hypoxic and non-hypoxic conditions. They found that 
activation of NOS2 sufficient to yield approximately 1 
μmol/L NO, at elevated oxygen concentrations, resulted 
in significant HIF-1a accumulation, even when there was 
sufficient oxygen for prolyl hydroxylation-mediated HIF-
1a degradation. This observation and those described 
by other authors[117-119,123], strongly suggest that HIF-
1a accumulation by NO is independent of oxygen 
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Figure 2  The role of nitric oxide as a regulator of mitochondrial function, metabolism and the hypoxia response. The wide range of functions controlled by nitric 
oxide (NO) is a consequence of its dose-dependent dual roles. Physiological concentrations of NO inhibit cytochrome c oxidase in a reversible manner in competition with 
O2. This interaction depends on NO and oxygen concentrations and the redox state of the enzyme. Because of this, it has been reported that NO might be a regulator 
of cell respiration, modulating metabolic changes responsible for an increase in glycolytic pathway flux to maintain energy homeostasis. On the other hand, NO can 
also regulate the hypoxia response through hypoxia inducible factor-1α (HIF-1α). In a normoxic microenvironment, NO induces HIF-1α accumulation in a mitochondrial-
dependent and -independent manner. Hypoxia conditions promote delayed cell differentiation. These facts indicate that NO might maintain pluripotency via regulation of 
metabolism and the hypoxia response. EM: Energy metabolism.
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concentration. Moreover, this activity was shown to be 
independent of any action on the respiratory chain, 
since it was not affected by compounds that inhibit 
mitochondrial respiration at different stages and also 
occurred in cells lacking a functional respiratory chain. 
In this case, it is possible that the stabilisation of HIF-
1a was the result of S-nitrosylation of thiol groups of the 
HIF-1a protein[119,123] or by the direct inactivation of prolyl 
hydroxylases (PHD) by NO as suggested by Metzen et 
al[124]. 
NO inhibits HIF-1a accumulation in a concentration-
dependent manner in cells subject to a low oxygen 
concentration (3%O2) which would normally allow HIF-1a 
levels to increase[18]. Under hypoxia, endogenous NO (400 
nmol/L) destabilises HIF-1a by inhibiting mitochondrial 
respiration, thus increasing the cytosolic oxygen 
concentration where PHD2 is mainly located[125,126].
Unlike the destabilising effect of NO on HIF-1a, its 
effect promoting HIF-1a accumulation was correlated 
with inhibition of cell respiration and could be mimicked 
by all mitochondrial respiration inhibitors, indicating 
that it is dependent on the respiratory chain. However, 
under normoxia (21%O2) and 1 mmol/L of DETA-
NO, HIF-1a accumulates in a way that mimics the 
stabilising effect observed at high NO concentrations 
under hypoxia. Interestingly, this explains why, although 
all other inhibitors completely destabilise HIF-1a, NO 
does not, since its stabilising effect is apparent even at 
intermediate NO concentrations, something not seen 
for the other inhibitors. It has been proposed that the 
destabilising effect of NO on HIF-1a may be due to the 
inhibition of Complex I-dependent generation of super-
oxide anion (O2•-), and consequently, peroxynitrite 
(ONOO−)[122]. In conclusion, at low concentrations, NO 
has the ability to destabilise HIF-1a under hypoxia, an 
effect that is mitochondria-dependent, while at high 
concentrations, it can stabilise HIF-1a in a mitochondria-
independent manner. It is also possible that the effect 
of low NO concentrations is part of its physiological 
regulatory mechanism related to the inhibition of CcO. 
The stabilisation of HIF-1a by high NO concentrations 
and its synergy with the hypoxic stabilisation of HIF-
1a may play a role in pathological conditions such as 
inflammation, degeneration and cancer, in which high 
concentrations of NO, hypoxia and HIF-1a stabilisation 
have been described[18,125,126].
There are various potential mechanisms by which 
NO regulates HIF-1a activity. First, NO donors, as 
well as other growth factors[127,128], stimulate HIF-1a 
translation by activating the PI3K/Akt pathway[129]. 
Second, the NO donors S-nitrosoglutathione (GSNO) and 
S-nitroso-N-acetylpenicillamine (SNAP) increase HIF-
1a accumulation by inhibiting the interaction between 
VHL and hydroxylated HIF-1a, without blocking PHD2-
mediated hydroxylation[124,130,131]. Third, biotin switch 
assays have reveal that endogenous and exogenous 
NO produce the S-nitrosylation of the HIF-1a trans-
activation domain (amino acids 727-826)[132,133] and the 
oxygen-dependent degradation domain[123,134]. Fourth, 
direct inhibition of HIF-1a asparagine hydroxylation 
activity by SNAP permits interaction between HIF-
1a and p300/CBP[130]. Fifth, the dependence of VHL 
recruitment on proline hydroxylation[124] is controversial, 
as some authors reported that GSNO and SNAP inhibit 
it, while others have shown that SNP, PAPA NONOate, 
and MAHMA NONOate increase it[135]. However, using a 
specific antibody, Li et al[134] were able to detect proline-
hydroxylated HIF-1a. It was also reported that mouse 
HIF-1a Cys533 is nitrosylated and that this S-nitrosylation 
does not inhibit proline-hydroxylation[134]. 
Park et al[130] concluded that SNAP blocks VHL 
recruitment but not HIF-1a proline hydroxylation. This 
inhibitory effect is reversed by reducing agents such 
as vitamin C and Fe (II)[130]. They proposed that NO 
increases p300/CBP recruitment, not by HIF-1a Cys800 
nitrosylation, but by inhibiting HIF-1a via asparagine 
hydroxylases. They also suggested that SNAP inhibited 
this enzyme by oxidation of the Fe (II) in its catalytic 
core or by nitrosylation of some cysteine residues[136]. 
CONCLUSION
In this review we have studied in detail the actions 
of NO on specific cell signalling pathways involved 
in embryonic development, placing emphasis on the 
regulation of the hypoxia response. We have extensively 
analysed the dual role of NO. Low NO concentrations 
delay stem cell differentiation, inducing the expression 
of Nanog, Oct4 and Sox2, and the activation of 
survival pathways. At high concentrations, NO induces 
differentiation events with the expression of early 
differentiation markers as well as promoting apoptosis.
Due to these activities, NO represents a promising tool 
for culturing pluripotent cell lines in an undifferentiated 
state, as it has been proved that it consistently promotes 
the maintenance of pluripotency and survival. Thus, NO 
could enhance the pluripotency-promoting activities of 
factors such as LIF or bFGF. Moreover, studies based in 
the generation of chemically-defined xeno-free media 
using NO to maintain pluripotency are being carried out 
by our group, which would not only reduce costs, but 
also would avoid animal contamination issues.
Stem cell culture under hypoxic conditions helps 
prevent spontaneous differentiation. This is relevant for 
the design of better strategies for directing differentiation 
towards specific cell types. The generation of hypoxic 
cell culture microenvironments can be costly, such as 
maintaining bioreactors with hypoxic atmospheres. 
Knowing how NO regulates cellular respiration opens 
up the possibility of using exposure to low NO levels to 
mimic the hypoxia response under aerobic conditions 
by inducing HIF-1a. Activation of this master hypoxia 
response regulator would up-regulate glycolytic genes 
and help maintain energy homeostasis. 
On the other hand, high NO levels can be used 
to develop differentiation protocols for differentiating 
pluripotent cells into the three germinal lines (ectoderm, 
mesoderm and endoderm). In this context, NO has been 
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used to differentiate cells to cardiomyocytes, vascular 
and endothelial tissues, neurons, astrocytes, erythroid 
and myeloid cells, bone, chondrocytes and definitive 
endoderm. To sum up, the studies reviewed here underline 
the diverse range of potential applications for NO in stem 
cell biotechnology.
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